Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration

22 Nov 2022

Abstract excerpt

New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately 10% of tumors show primary resistance, whereas acquired resistance appears to be an almost ubiquitous occurrence,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36498861
DOI: 10.3390/ijms232314534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA ExplorationPMID 36498861Read ↗

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity Read ↗

Genetic Signature of Breast Cancer Defines Therapeutic Interventions and Indicates Early Drug Resistance.Semantic proximity Read ↗

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor TreatmentSemantic proximity Read ↗

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine TherapySemantic proximity Read ↗

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read ↗

Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology.Semantic proximity Read ↗

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerSemantic proximity Read ↗

The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast CancerSemantic proximity Read ↗

Breast cancer biomarkers and molecular medicine.Semantic proximity Read ↗

CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.